Gautham Marigowda, Fang Liu, David Waltz Journal of Cystic Fibrosis

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

William G. Flight, Jonathan Shaw, Susan Johnson, A

Felix Ratjen, Paul Koker, David E

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy Edith T. Zemanick, J. Kirk Harris,

Patrick O. Sobande, James D. Acton, Raouf S. Amin, Jeanne Weiland

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Delayed publication of clinical trials in cystic fibrosis

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR Jennifer L. Taylor-Cousar, Manu Jain, Tara.

The Journal of Cystic Fibrosis: Sunny perspectives

Vitamin A and lung function in CF

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Cystic fibrosis related diabetes in an extremely young patient

Physiologic endpoints for clinical studies for cystic fibrosis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Valerie Waters, Eshetu G

Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis Talissa A. Altes, Mac Johnson, Meredith.

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Voriconazole therapy in children with cystic fibrosis

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup:

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Journal of Cystic Fibrosis

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Journal of Cystic Fibrosis

Robert P. Thomen, Laura L. Walkup, David J. Roach, Zackary I

Cystic fibrosis and pregnancy in the modern era: A case control study

Presentation transcript:

Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy Gautham Marigowda, Fang Liu, David Waltz Journal of Cystic Fibrosis Volume 16, Issue 2, Pages 246-249 (March 2017) DOI: 10.1016/j.jcf.2016.11.001 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Percent predicted FEV1 before and after LUM/IVA administration in the absence of LABD (period 1). Data are mean ppFEV1 during period 1 and error bars indicate standard error. FEV1, forced expiratory volume in 1s; LUM/IVA, lumacaftor/ivacaftor; SABD, short-acting bronchodilator; SE, standard error. Journal of Cystic Fibrosis 2017 16, 246-249DOI: (10.1016/j.jcf.2016.11.001) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Percent predicted FEV1 before and after LUM/IVA administration in the presence of LABD (periods 2 and 3). Data are mean ppFEV1 during periods 2 and 3 (average) and error bars indicate standard error. FEV1, forced expiratory volume in 1s; LABD, long-acting bronchodilator; LUM/IVA, lumacaftor/ivacaftor; SABD, short-acting bronchodilator; SE, standard error. Journal of Cystic Fibrosis 2017 16, 246-249DOI: (10.1016/j.jcf.2016.11.001) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Absolute change in ppFEV1 at 4h post LUM/IVA in the absence of a bronchodilator (day 1). Waterfall plot showing the absolute change in ppFEV1 at 4h post LUM/IVA on day 1 in the absence of a bronchodilator. Each bar represents data for an individual subject. LUM/IVA, lumacaftor/ivacaftor; ppFEV1, percent predicted forced expiratory volume in 1s. Journal of Cystic Fibrosis 2017 16, 246-249DOI: (10.1016/j.jcf.2016.11.001) Copyright © 2016 The Authors Terms and Conditions